The GLP-1 receptor agonist exenatide failed to meet its primary outcome in a phase III trial of Parkinson's disease patients.
Peptides have gained significant attention in research due to their possible role in regulating various physiological ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback